March 2025 in “International Journal of Dermatology” Baricitinib may help people with long-term alopecia areata.
May 2026 in “Case Reports in Dermatology” This document discusses a case of a 31-year-old kidney transplant recipient who developed significant alopecia due to tacrolimus-based immunosuppression. The hair loss had a psychological impact, leading the patient to consider stopping treatment. A switch to cyclosporine A improved hair regrowth and well-being. A literature review identified four similar cases linking alopecia to immunosuppressive therapy in organ transplant recipients. The study emphasizes the importance of awareness among clinicians about hair disorders as side effects of immunosuppression, which can affect treatment adherence and quality of life. Regular dermatological assessments and personalized management, including adjusting immunosuppressive regimens, are recommended to mitigate these issues.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
17 citations
,
October 2009 in “Dermatology” Ultraviolet light helped hair growth more effectively than triamcinolone acetonide.
April 2022 in “Reactions Weekly” 2 citations
,
May 2024 in “International Journal of Dermatology”
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
5 citations
,
January 2023 in “IDCases” Albendazole and praziquantel can cause severe side effects, especially with prolonged use or liver issues.
1 citations
,
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated a rare skin condition with ash-gray patches.